Abbott India Ltd. NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

30970.00 40.00 (0.13%)

13,262

NSE+BSE Volume

NSE 17 Sep, 2025 3:31 PM (IST)

Abbott India Ltd. share price target

Abbott India Ltd. has an average share price target of 35626. The consensus estimate represents an upside of 15.03% from the last price of 30970. View 8 reports from 3 analysts offering long-term price targets for Abbott India Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	18 Sep 2025	Abbott	Consensus Share Price Target	30970.00	34237.00	-	10.55	buy	pdf Detailed Estimates
	10 Feb 2023	Abbott	Sharekhan Target	30970.00	25243.00	20680.15 (49.76%)	Target met	Buy	pdf post cache		Broker Report Abbott India Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	17 Nov 2022	Abbott	ICICI Direct Target	30970.00	21725.00	19493.95 (58.87%)	Target met	Hold	pdf post cache		Broker Report Abbott India ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	15 Nov 2022	Abbott	ICICI Securities Limited Target	30970.00	20523.00	19651.45 (57.60%)	Target met	Hold	pdf post cache		Broker Report In-line revenues; subdued costs lift margins ICICI Securities Limited Abbott India’s (Abbott) Q2FY23 performance beat our estimates on the profitability front while revenues were largely in-line. pdf Copy Link Share on Share on Share on Share on Alert
	16 Aug 2022	Abbott	ICICI Direct Reco Target	30970.00	21140.00	19069.75 (62.40%)	Target met	Hold	pdf post cache		Broker Report Abbott India ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	12 Aug 2022	Abbott	Axis Direct Target	30970.00	20800.00	18793.35 (64.79%)	Target met	Buy	pdf post cache		Broker Report Result Update:Abbott India Axis Direct Abbott India's strategy of Beyond the Pill' comprising awareness, diagnosis, treatment and compliance for consumers is expected to deliver continued growth for the business. Therefore, we maintain a BUY rating on the stock with a Target Price of Rs 20,800/share. pdf Copy Link Share on Share on Share on Share on Alert
	11 Aug 2022	Abbott	ICICI Securities Limited Reco Target	30970.00	19478.00	19604.20 (57.98%)	Target met	Hold	pdf post cache		Broker Report Margins contract; stock fairly priced ICICI Securities Limited Abbott India’s (AIL) Q1FY23 performance was below our estimate on the profitability front. pdf Copy Link Share on Share on Share on Share on Alert
	18 May 2022	Abbott	Axis Direct	30970.00	20000.00	17875.55 (73.25%)	Target met	Buy	pdf post cache		Broker Report Result Update:Abbott India Axis Direct We maintain a BUY rating on the stock with a Target Price of Rs 20,000/share. pdf Copy Link Share on Share on Share on Share on Alert
	18 May 2022	Abbott	ICICI Direct	30970.00	20560.00	17875.55 (73.25%)	Target met	Buy	pdf post cache		Broker Report Abbott India ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	11 Feb 2022	Abbott	ICICI Securities Limited Target	30970.00	19840.00	16537.05 (87.28%)	Target met	Buy	pdf post cache		Broker Report Abbott India ICICI Securities Limited Abbott's top 10 brands - (Mixtard, Thyronorm, Novomix, Udiliv, Duphaston) together posted revenue CAGR of ~7% MAT, December 2018-22 Abbott has 140+ brands in segments of women's health, gastroenterology,... pdf Copy Link Share on Share on Share on Share on Alert
	10 Feb 2022	Abbott	Axis Direct	30970.00	20000.00	16615.00 (86.40%)	Target met	Buy	pdf post cache		Broker Report Result Update:Abbott India Axis Direct The company is expected to report Revenue/PAT CAGR of 11.1% and 11.3% 0ver FY21-FY24E backed by stable sales in the Duphaston brand, an increase in volume in the Thyronorm brand, and a pick-up in the IPM growth. Therefore, we recommend a BUY rating on the stock with a Target Price of Rs 20,000/share pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners